Madrigal Pharmaceuticals (MDGL) is back in focus after its first quarter 2026 earnings, where Rezdiffra delivered 127% year over year net sales growth to US$311.3 million, while the company still ...
In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic ...
Madrigal Pharmaceuticals signed a potential $1 billion deal to expand its pipeline of MASH liver disease treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results